PA8794801A1 - Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion - Google Patents

Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion

Info

Publication number
PA8794801A1
PA8794801A1 PA20088794801A PA8794801A PA8794801A1 PA 8794801 A1 PA8794801 A1 PA 8794801A1 PA 20088794801 A PA20088794801 A PA 20088794801A PA 8794801 A PA8794801 A PA 8794801A PA 8794801 A1 PA8794801 A1 PA 8794801A1
Authority
PA
Panama
Prior art keywords
urato
profilaxis
treatment
caused
sequels
Prior art date
Application number
PA20088794801A
Other languages
English (en)
Inventor
Wolfgang Linz
Matthias Schaefer
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8794801A1 publication Critical patent/PA8794801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCIÓN SE REFIERE AL USO DE UNA URATO OXIDASA,DE PREFERENCIA URATO OXIDASA RECOMBINATE,POR EJEMPLO RASBURICASA,PARA PRODUCIR UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE TRASTORNOS O SECUELAS INDIRECTAS DEL CORAZÓN CAUSADOS POR SUCESOS ISQUÉMICOS O DE REPERFUSIÓN,POR EJEMPLO DURANTE Y DESPUÉS DE CIRUGÍA CARDIACA TAL COMO CBG(BYPASS CORONARIO ARTERIAL POR INJERTO),PCI(INTERVENCIÓN CORONARIA PERCUTÁNEA),TRAPLANTES,POST-INFARTO DE MIOCARDIO Y PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDAD ARTERIAL CORONARIA O FALLO CARDIACO,POR EJEMPLO FALLO CARDIACO CONGESTIVO.
PA20088794801A 2007-09-05 2008-09-03 Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion PA8794801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291072 2007-09-05

Publications (1)

Publication Number Publication Date
PA8794801A1 true PA8794801A1 (es) 2009-04-23

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088794801A PA8794801A1 (es) 2007-09-05 2008-09-03 Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion

Country Status (22)

Country Link
US (1) US20100266567A1 (es)
EP (1) EP2197550A1 (es)
JP (1) JP2011509920A (es)
KR (1) KR20100053609A (es)
CN (1) CN101801460A (es)
AR (1) AR068360A1 (es)
AU (1) AU2008295145B2 (es)
BR (1) BRPI0816406A2 (es)
CA (1) CA2697929A1 (es)
CL (1) CL2008002623A1 (es)
CO (1) CO6260090A2 (es)
IL (1) IL204259A (es)
MA (1) MA31624B1 (es)
MX (1) MX2010001976A (es)
MY (1) MY183770A (es)
NZ (1) NZ583635A (es)
PA (1) PA8794801A1 (es)
PE (1) PE20090642A1 (es)
TW (1) TW200927929A (es)
UY (1) UY31320A1 (es)
WO (1) WO2009030373A1 (es)
ZA (1) ZA201000774B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
CA2413201A1 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Treatment for cardiovascular disease
AU2003275160A1 (en) * 2002-09-20 2004-04-08 Oregon Health And Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
MXPA06009072A (es) * 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Also Published As

Publication number Publication date
PE20090642A1 (es) 2009-06-18
CL2008002623A1 (es) 2009-01-16
UY31320A1 (es) 2009-04-30
NZ583635A (en) 2011-06-30
CA2697929A1 (en) 2009-03-12
ZA201000774B (en) 2011-04-28
CN101801460A (zh) 2010-08-11
AR068360A1 (es) 2009-11-11
MX2010001976A (es) 2010-03-10
AU2008295145A1 (en) 2009-03-12
WO2009030373A1 (en) 2009-03-12
AU2008295145B2 (en) 2013-12-05
RU2010112867A (ru) 2011-10-10
MY183770A (en) 2021-03-12
US20100266567A1 (en) 2010-10-21
JP2011509920A (ja) 2011-03-31
IL204259A (en) 2013-06-27
CO6260090A2 (es) 2011-03-22
TW200927929A (en) 2009-07-01
EP2197550A1 (en) 2010-06-23
MA31624B1 (fr) 2010-08-02
KR20100053609A (ko) 2010-05-20
BRPI0816406A2 (pt) 2017-05-16

Similar Documents

Publication Publication Date Title
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
UA99167C2 (ru) Лечение дегенерации межреберных дисков с использованием клеток, полученных из ткани пуповины человека
NO20084919L (no) Oksadiazolidindionforbindelse
CL2007001749A1 (es) Compuesto derivado de 2-arilamino-4-(heterociclo)aminopirimidina, inhibidores de la proteina quinasa c-alfa; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes, cancer, enfermedad cardiaca coronaria, aterosclerosis, entre otras.
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
CL2008002351A1 (es) Compuestos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
BR112012010766A2 (pt) composições e métodos de tratamento da colite e de outras doenças instestinais
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
PA8635301A1 (es) Derivados sustituidos del dioxido de oxazolbenzoisotiazol, procedimiento para su preparacion y su uso
UY29300A1 (es) Compuestos quimicos
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
UY29264A1 (es) Tiazolidinonas metasustituidas, su preparación y su uso como medicamento
CR9722A (es) Derivados de benzilpiperazina y su uso medico
UY28443A1 (es) Derivados sustituidos del dióxido de tiazol-benzoisotiazol, procedimiento para su preparación y su uso.
MX2009010778A (es) Composiciones y metodos para el tratamiento de insuficiencia cardiaca.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
BRPI0606140A2 (pt) tiazolidinonas, preparação e uso das mesmas como medicamento
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
CO6440583A2 (es) Derivados de quinazolinadiona, su preparación y sus diversas aplicaciones terapéuticas
CO6531499A2 (es) Uso de ranolazina para el tratameinto de enfermedades cardiovasculares